SCHEMBL3528287

SCHEMBL3528287

CCOC(=O)C(C)OCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1cc(OC)ccc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 2/20 0.45
ALDH1A1 P00352 6/20 0.45
TP53 P04637 2/20 0.44
MAPT P10636 3/20 0.44
WDR5 P61964 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
SLC16A3 O15427 1/20 0.43
SLC16A7 O60669 1/20 0.43
SLC16A8 O95907 1/20 0.43
HTR5A P47898 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529189 0.88 MAPT (0.42) NPSR1HTTALDH1A1TP53MAPT
SCHEMBL3523974 0.81 ALDH1A1 (0.48) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3524449 0.80 ALDH1A1 (0.53) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3522744 0.78 ALDH1A1 (0.48) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3524909 0.77 MAPT (0.43) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3524515 0.76 SMN1; SMN2 (0.48) HTTLMNAALDH1A1MAPTKMT2A
SCHEMBL3526713 0.74 ALDH1A1 (0.46) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3524812 0.74 ALDH1A1 (0.46) NPSR1HTTLMNAALDH1A1TP53
SCHEMBL3523093 0.74 HTT (0.48) HTTLMNAALDH1A1TP53MAPT
SCHEMBL3528196 0.72 PTGES2 (0.44) HTTALDH1A1TP53KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP NPSR1 669/4885HTT 73/4885LMNA 849/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG NPSR1 239/4885HTT 229/4885LMNA 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.